- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01192685
Transcranial Magnetic Stimulation in Major Depression With EEG and Near Infrared Spectroscopy (NIRS) Monitoring
April 19, 2017 updated by: Boston University
Transcranial Magnetic Stimulation in Major Depression With EEG and NIRS Monitoring
This a 12- week study (1-4 week screening, 6 weeks treatment, 2 weeks follow-up) outpatient open label clinical trial.
Twenty-five subjects diagnosed with depression with a Montgomery Asberg Depression Rating Scale (MADRAS) score of 26 or higher, will be enrolled into this trial, up to fifty subjects will be consented.
The primary purpose of the current study is to determine: 1) if changes in electrical activity of the brain measured by EEG in specific areas is associated with changes in the blood flow of the brain 2) Which areas of the brain show changes in electrical activity and treatment response.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Transcranial magnetic stimulation (TMS) has demonstrated efficacy as a treatment for major depression.
No objective markers have been identified that indicate which patients are most likely to respond to TMS therapy.
The goal of the present investigation is to determine whether an electroencephalographic measure called cordance or a measure of blood flow in the frontal brain, as measured by near infrared spectroscopy (NIRS) can serve as predictors of outcome with TMS therapy in depression.
Subjects with depression will be treated in this study for 6 weeks with TMS.
Frontal brain blood flow measured using NIRS will be assessed prior to TMS therapy, and repeatedly thereafter.
EEG cordance will also be obtained following a similar schedule.
Measures of depression and other psychiatric disorders will be collected prior to, during and for 2 weeks after the completion of TMS treatment.
The correlation between these measures and the EEG and NIRS measures will then be determined to see if these latter measures are predictive of improvement in depression.
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria List
- Depressive disorder Diagnostic Statistical Manual of Mental Disorders, fourth Edition, Text Revision (DSM-IV-TR).
- MADRAS score of 26 or above and history of depression, as defined by meeting DSM-IV criteria for major depression, dysthymic disorder, or substance-induced mood disorder.
- Male or female aged 18 to 65.
- Females who are not pregnant or nursing.
- Individuals able to provide informed written consent and are able to comply with study procedures.
- Subjects who have received or are receiving anti-depressant medication.
- Patients who are depressed as assessed by the above criteria and have not had optimum response to their antidepressant medication in their current episode.
Exclusion criteria List
- Any Axis I diagnosis that, in the opinion of the investigators, may interfere with the course of the trial.
- Any current diagnoses of alcohol abuse or dependence.
- Any current substance use disorder.
- Medical or neurological illness that in the investigators judgment would make study compliance difficult or would be a contraindication for use with TMS.
- Currently receiving any medication that markedly increases the risks for seizures, for example: tricyclic antidepressants, INH, meperidine, lidocaine, and clozapine.
- Subjects who have implanted metallic devices or non-removable metallic objects in or around the head that can be magnetized, however metal fillings, braces, and dental implants are acceptable.
- Subjects who have implanted devices that emit physiological signals including cardioverter defibrillators (ICDs), and vagus nerve stimulators.
- Subjects who have received any investigational drug during the prior 30 days.
- Clinically significant abnormal lab values as assesses by the Investigator.
- Risk for suicidal behavior based on clinician assessment and a score of greater than 5 on the suicidal thought item of the MADRS or a score of 4 on the suicide item of the Hamilton Depression rating scale.
- Subjects who have had a serious suicide attempt in the past year as assessed by the Investigator.
- Current other somatic antidepressant therapy, i.e. vagus nerve stimulation, electroconvulsive therapy, or phototherapy.
- Started psychotherapy in the past 30 days.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Depressed outpatients treated with TMS
This a 12- week study (1-4 week screening, 6 weeks treatment, 2 weeks follow-up) outpatient open label clinical trial.
Twenty-five subjects diagnosed with depression with a Montgomery Asberg Depression Rating Scale (MADRAS) score of 26 or higher, will be enrolled into this trial, up to fifty subjects will be consented.
Transcranial Magnetic Stimulation (TMS) will be administered to subjects 5 days a week for 6 weeks.
Near infrared spectroscopy (NIRS), a spectroscopic method that uses the near infrared region of the electromagnetic spectrum (from about 700 nm to 2500 nm), will be used to assess blood flow in the brain.
|
TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The correlations between EEG cordance or task-induced changes in frontal total Hb levels
Time Frame: 6 weeks
|
The primary outcome will be the correlations between EEG cordance or task-induced changes in frontal total Hb levels and changes in MADRAS scores between baseline and the last treatment day.
Correlations between these measures will be determined between other cordance and total Hb levels obtained after the first week of treatment and MADRAS changes for the last day of treatment.
Similar analyses will be conducted for changes in MADRAS scores between baseline and the follow-up visit.
|
6 weeks
|
Changes in MADRAS scores between baseline and the last treatment day
Time Frame: 6 Weeks
|
The primary outcomes will be the correlations between EEG cordance or task-induced changes in frontal total Hb levels and changes in MADRAS scores between baseline and the last treatment day.
Correlations between these measures will be determined between other cordance and total Hb levels obtained after the first week of treatment and MADRAS changes for the last day of treatment.
Similar analyses will be conducted for changes in MADRAS scores between baseline and the follow-up visit.
|
6 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ofra Sarid-Segal, MD, Boston University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2012
Primary Completion (Actual)
December 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
August 30, 2010
First Submitted That Met QC Criteria
August 31, 2010
First Posted (Estimate)
September 1, 2010
Study Record Updates
Last Update Posted (Actual)
April 20, 2017
Last Update Submitted That Met QC Criteria
April 19, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-29098
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Lawson Health Research InstituteTerminated
Clinical Trials on Transcranial Magnetic Stimulation (TMS)
-
Emory UniversityNational Institute of Mental Health (NIMH)Recruiting
-
Centre Hospitalier St AnneNot yet recruitingTreatment Resistant Schizophrenia
-
Northwestern UniversityCompletedHealthyUnited States
-
University of FloridaActive, not recruiting
-
Huashan HospitalUnknown
-
University of California, San DiegoNational Institutes of Health (NIH)RecruitingMajor Depressive DisorderUnited States, Australia
-
University of ManitobaRecruiting
-
University of PennsylvaniaCompletedAttention Deficit Disorder With Hyperactivity (ADHD)United States
-
Beth Israel Deaconess Medical CenterTerminated
-
Northwestern UniversityRecruiting